Diagnosing and treating rare and orphan diseases remains one of the life science sector’s great challenges. This is compounded by small patient populations, which are …
Despite more people surviving cancer than ever before, a staggering 9.6 million people worldwide died from cancer in 20181, making the need for new drugs …
One of the most widely recognised limitations of traditional randomised clinical trials (RCTs) is that the observation period and treatment courses reflect only a fraction …
The pharmaceutical sector’s fundamental purpose of advancing human health and its ambition to deliver drugs to market as rapidly, safely and cost-effectively as possible has …
Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.
